Form 6-K Summary
Registrant: NLS Pharmaceutics Ltd. (the request metadata identifies Newcelx Ltd., which does not match the filing text).
Reporting period: March 2021, Report No. 2; filed March 10, 2021. The filing reports corporate management and auditor changes rather than financial results.
Business Context and Reporting Period
NLS Pharmaceutics Ltd. is a Swiss foreign private issuer filing under Form 20-F. Its principal executive offices are in Stans, Switzerland.
Financial Metrics and Liquidity
- The filing does not provide current revenue, profit, cash flow, margin, debt, liquidity, or balance-sheet figures.
- The former auditor’s reports on the 2019 and 2018 financial statements included an explanatory paragraph regarding substantial doubt about the Company’s ability to continue as a going concern.
Material Changes
- Effective March 4, 2021, Rob Dickey IV ceased serving as Chief Financial Officer for personal reasons. The Company stated the departure was not related to any disagreement.
- The Company initiated a search for a successor CFO; no successor was identified in the filing.
- Effective March 4, 2021, the Company dismissed Marcum LLP and engaged PricewaterhouseCoopers AG as its independent registered public accounting firm.
- For fiscal years 2019 and 2018 and the interim period through March 4, 2021, the Company reported no auditor disagreements or reportable events, except for identified material weaknesses in internal control over financial reporting.
Guidance, Risks, Contingencies, and Unusual Items
- Reported internal-control weaknesses related to improper cutoff of accounts payable and accrued expenses in a previous period and accounting for complex transactions, including intangible assets and a licensing agreement.
- Historical going-concern uncertainty is a material risk disclosed through the former auditor’s explanatory paragraph.
- The Company stated that neither it nor anyone acting on its behalf consulted the new auditor during the specified periods regarding accounting principles, potential audit opinions, disagreements, or reportable events.
- Marcum LLP’s response letter was filed as Exhibit 16.1.
Investor Verification Items
- Verify the registrant identity, because the provided metadata names Newcelx Ltd. while the filing names NLS Pharmaceutics Ltd.
- Review the Company’s subsequent filings for the appointment of a permanent CFO.
- Assess whether the reported material weaknesses have been remediated.
- Review the latest audited financial statements for updated going-concern, liquidity, debt, and operating results information.
- Read Exhibit 16.1 to confirm Marcum LLP’s response to the auditor-change disclosures.